[Analysis of the clinical application of epidermal growth factor ("Heberprot-P") and bioplastic material ("Collost") in treatment of skin and soft tissues defects in patients with diabetic foot syndrome].

Autor:	Dibirov MD; Department of Surgical Diseases and Clinical Angiology, Moscow State University of Medicine and Dentistry; City Clinical Hospital #81, Moscow., Gadzhimuradov RU; Department of Surgical Diseases and Clinical Angiology, Moscow State University of Medicine and Dentistry; City Clinical Hospital #81, Moscow., Koreyba KA; Department of General Surgery, Kazan State Medical University; 'Diabetic Foot' Center, Kazan.
Jazyk:	ruština
Zdroj:	Khirurgiia [Khirurgiia (Mosk)] 2016 (3), pp. 59-63.
DOI:	10.17116/hirurgia2016359-63
Abstrakt:	Relevance: Currently, there is increasing the number of diabetic foot patients with tissues defects. The local treatment of this pathology against the backdrop of diabetic angiopathy and polyneuropathy is a topical issue. Aim: Treatment of wound defects in patients with neuroischemic form of diabetic foot syndrome; study of the effectiveness of collagen implants and gene-therapy technologies in wound closure. Material and Methods: The comparative study was conducted for analyzing clinical effects of "Heberprot-P" and bioplastic material "Collost" on wound healing process in patients with verified diagnosis "diabetic foot syndrome" on the base of City Clinical Hospital №81(Moscow) and "Diabetic Foot" center (Kazan). Results: The article shows the availability, methodology, results of combination treatment of wound defects of lower limbs in DFS patients with gen-therapy methods and bioplastic materials based on native type I collagen. Conclusion: The use of bioplastic materials based on native type I collagen for treatment of tissue defects in patients with diabetic foot is preferably than the use of epidermal growth factor.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu